DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Bioactive CompoundsBioactive Compounds
  4. /Protein Kinase TargetsProtein Kinase Targets
  5. /PDGFRPDGFR
  6. /VorolanibVorolanib
Chemical structure of CAS 1013920-15-4

Vorolanib

In Stock•Starting at $228 for 5 mg•Purity ≥ 98%
CAS No.1013920-15-4
MDL No.N/A
MFC23H26FN5O3
MW439.50
InChI KeyKMIOJWCYOHBUJS-HAKPAVFJSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg98%$228In Stock
10 mg98%$366In Stock
25 mg98%$655In Stock
50 mg98%$1181In Stock
100 mg98%$1675In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1013920-15-4
Product NameVorolanib

Associated Conditions

age-related macular degeneration·small cell lung carcinoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo.

Microvascular research • Vol. 136 • 2021
PMID: 33610563DOI: 10.1016/j.mvr.2021.104146

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu • Vol. 33, Issue 1 • 2021
PMID: 33707933PMC: PMC7941683DOI: 10.21147/j.issn.1000-9604.2021.01.11

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.

EBioMedicine • Vol. 55 • 2020
PMID: 32335374PMC: PMC7184160DOI: 10.1016/j.ebiom.2020.102755

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats.

Journal of ophthalmology • Vol. 2017 • 2017
PMID: 29201457PMC: PMC5671735DOI: 10.1155/2017/6145651

Documentation

Similar Products

  • Sunitinib

    CAS No.557795-19-4

  • Toceranib

    CAS No.356068-94-5

  • Toceranib Phosphate

    CAS No.874819-74-6

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact